Menu

High-Profile Diabetes Study Retracted

The results, which could not be replicated, suggested that a hormone increased pancreatic β cell proliferation, supplanting insulin as a front-line diabetes treatment in mice.

Dec 28, 2016
Joshua A. Krisch

PIXABAY, STEVEPBIn 2013, Harvard University stem cell researcher Douglas Melton and colleagues described an innovative diabetes treatment that “could augment or replace insulin injections,” they wrote in a study published in Cell. The authors demonstrated that a hormone called betatrophin, or Angiopoietin-like protein 8 (Angptl8), could ramp up pancreatic β cell proliferation in mice, combatting insulin resistance.

But after multiple failed attempts to replicate the findings—and one study by Melton himself, published in PLOS ONECell has retracted the paper. “I wanted to make sure anyone doing a PubMed search would see this is our present view,” Melton told Retraction Watch. “It would be most unfortunate if a lab missed the PLOS ONE paper, then wasted time and effort trying to replicate our results.”

The once promising results began to unravel in 2014, when an independent team of researchers at Regeneron Pharmaceuticals published a paper in Cell that found Angptl8 did not influence β cell expansion. But then in 2015, researchers managed to replicate Melton’s findings in rats.

See “Diabetes 'Breakthrough' Breaks Up

Melton ultimately enlisted two other labs to help conduct a blinded experiment to determine whether his initial findings were correct. The initiative resulted in a PLOS ONE study in July 2016 that concluded that “the original paper describing the betatrophin hypothesis needs to be withdrawn.”

“It’s an example of how scientists can work together when they disagree, and come together to move the field forward,” Melton told Retraction Watch. “The history of science shows it is not a linear path.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.